Market research
EAST.V EastWest Bioscience Inc
V CAD Healthcare
Latest close
As of 05 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 3M
- P/E ratio
- 0.02
- Analyst target
- 461.63
- Dividend yield
- 0.0%
- Beta
- 0.7
Profile
Instrument facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- CA27783V1076
- Market cap
- 3M
- P/E ratio
- 0.02
- Analyst target
- 461.63
- Dividend yield
- 0.0%
- Beta
- 0.7
About
About EastWest Bioscience Inc
EastWest Bioscience Inc., a vertically-integrated wellness company, engages in the manufacturing and sale of hemp nutritional products in Canada and the United States. The company also operates Sangster's Health Center stores that sells supplements and wellness products through its franchise locations and online ecommerce platform. In addition, it is involved in the property management business. The company was founded in 2016 and is headquartered in Penticton, Canada.
Research context
EastWest Bioscience Inc appears in PyInvesting’s TSX Venture Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the EAST.V discussion.
5 years, 6 months ago
EastWest Bioscience Inc is currently in a long term downtrend where the price is trading 13.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.0.
EastWest Bioscience Inc's total revenue sank by 35.8% to $172K since the same quarter in the previous year.
Its net income has dropped by 638.8% to $-311K since the same quarter in the previous year.
Finally, its free cash flow fell by 285.8% to $-197K since the same quarter in the previous year.
Based on the above factors, EastWest Bioscience Inc gets an overall score of 1/5.